An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer

Nivolumab is an immune-checkpoint inhibitor (ICI) that can induce unique treatment-related toxicities, such as immune-related adverse events (irAEs). Myocarditis is a serious irAE with an incidence between 0.06% and 1.14%. Although the peak onset of irAE is generally within three months from the sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Naganuma, Ken, Horita, Yosuke, Matsuo, Keisuke, Miyama, Yu, Mihara, Yoshiaki, Yasuda, Masanori, Nakano, Shintaro, Hamaguchi, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593165/
https://www.ncbi.nlm.nih.gov/pubmed/35249925
http://dx.doi.org/10.2169/internalmedicine.9161-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593165/
https://www.ncbi.nlm.nih.gov/pubmed/35249925
http://dx.doi.org/10.2169/internalmedicine.9161-21

Ejemplares similares